Anhui Chengya

Anhui Chengya Pharmaceutical is a Chinese pharmaceutical company based in Hefei, Anhui Province, specializing in the research, development, and manufacturing of chemical drugs. The company focuses primarily on the development of high-quality generic medications and active pharmaceutical ingredients (APIs) across therapeutic areas such as cardiovascular disease, metabolic disorders, and immunology. Its commercial portfolio includes bioequivalent versions of major small molecule drugs, including the anticoagulants Rivaroxaban and Apixaban, as well as the antidiabetic agent Linagliptin. Anhui Chengya operates integrated facilities that comply with Good Manufacturing Practice (GMP) standards, supporting both domestic supply and international export. The company aims to provide affordable healthcare solutions through efficient chemical synthesis and rigorous quality control processes.